Akums Drugs and Pharmaceuticals Limited has informed the Exchange about General Updates_Resignation of Mr. Amrut Medhekar, CEO-CDMO w.e.f 15.07.2025

CEO resignedKey managerial personnel resignedManagement Changes View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹582.20

prior close

₹595.50

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-1.0% vs market

Pharmaceuticals peers, median of 147sector+0.1%-1.3% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.9

15m

+1.9

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-0.1-1.0+0.1-1.3

Next day

-1.1+0.2-1.3-0.0-1.1

-1.9+0.6-2.5+0.8-2.7

-2.2+0.9-3.1+0.3-2.5

-2.7+1.0-3.7+0.0-2.7

-3.4+0.7-4.1-0.6-2.8

-3.7+1.8-5.4+0.0-3.7

15d

-4.0+1.7-5.6-0.8-3.2

+1.4+3.1-1.7-0.8+2.2

-9.5+1.7-11.2+0.6-10.1

-19.7-1.0-18.7-2.9-16.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs informed the exchanges that its board has accepted the resignation of Mr. Amrut Medhekar, CEO-CDMO (Chief Executive Officer – Contract Development and Manufacturing Organization), effective July 15, 2025. The resignation letter with reasons was attached to the filing. In the same board meeting held on May 26, 2025, the company also approved its audited standalone and consolidated financial results for FY25. On a standalone basis, Akums swung from a Rs 1,654.51 million loss in FY24 to a net profit of Rs 1,609.98 million in FY25, with revenue dipping to Rs 14,359.76 million from Rs 15,382.40 million. The board also re-appointed the cost auditor and appointed a new secretarial auditor for FY25-29. The 21st AGM is scheduled for July 18, 2025.

Likely market impact

The exit of the CEO-CDMO, who leads a key business vertical, may raise short-term governance concerns for investors even though it takes effect nearly two months later. Separately, the FY25 turnaround to profit is positive, but the auditor has flagged an ongoing Income Tax search and seizure (Jan 15-21, 2025) at the company's offices and key managerial personnel's residences, whose outcome remains uncertain and could weigh on the stock.